Name: Pfizer Inc. (NYSE:PFE) | Common-Size Liabilities and Stockholders’ Equity
Creator: Stock Analysis on Net

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Pfizer Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term borrowings, including current portion of long-term debt	3.25%	4.57%	1.49%	1.23%	1.75%
Trade accounts payable	2.64%	2.96%	3.45%	3.07%	2.79%
Dividends payable	1.14%	1.05%	1.17%	1.24%	1.40%
Income taxes payable	1.36%	1.04%	0.80%	0.70%	0.68%
Accrued compensation and related items	1.80%	1.23%	1.73%	1.84%	1.98%
Deferred revenues	0.71%	1.19%	1.28%	1.69%	0.72%
Other current liabilities	9.24%	9.07%	11.44%	13.74%	7.47%
Current liabilities	20.15%	21.10%	21.37%	23.51%	16.81%
Long-term debt, excluding current portion	26.90%	27.17%	16.68%	19.94%	24.08%
Pension and postretirement benefit obligations	0.99%	0.96%	1.14%	2.05%	3.51%
Noncurrent deferred tax liabilities	0.99%	0.28%	0.52%	0.19%	2.63%
Other taxes payable	2.86%	3.77%	4.98%	6.24%	7.50%
Other noncurrent liabilities	6.63%	7.30%	6.68%	5.37%	4.32%
Noncurrent liabilities	38.38%	39.48%	29.99%	33.80%	42.04%
Total liabilities	58.53%	60.58%	51.36%	57.32%	58.84%
Common stock, $0.05 par value	0.22%	0.21%	0.24%	0.26%	0.30%
Additional paid-in capital	43.86%	40.90%	46.55%	49.92%	57.50%
Treasury stock, shares at cost	-53.78%	-50.55%	-57.79%	-61.36%	-71.96%
Retained earnings	54.70%	52.25%	63.72%	56.97%	62.74%
Accumulated other comprehensive loss	-3.67%	-3.51%	-4.21%	-3.25%	-7.58%
Total Pfizer Inc. shareholders’ equity	41.33%	39.30%	48.51%	42.54%	41.00%
Equity attributable to noncontrolling interests	0.14%	0.12%	0.13%	0.14%	0.15%
Total equity	41.47%	39.42%	48.64%	42.68%	41.16%
Total liabilities and equity	100.00%	100.00%	100.00%	100.00%	100.00%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Short-term borrowings, including current portion of long-term debt: This metric exhibited a fluctuating trend, initially decreasing from 1.75% in 2020 to 1.23% in 2021, then increasing to a notable peak of 4.57% in 2023 before declining to 3.25% in 2024.
Trade accounts payable: The proportion gradually increased from 2.79% in 2020 to 3.45% in 2022, followed by a decline over the next two years to 2.64% in 2024.
Dividends payable: There was a consistent decline in this liability item from 1.40% in 2020 to a low of 1.05% in 2023, with a slight uptick to 1.14% in 2024.
Income taxes payable: This category showed a steady rising trend, increasing from 0.68% in 2020 to 1.36% in 2024, indicating growing tax obligations relative to total liabilities and equity.
Accrued compensation and related items: Values declined gradually from 1.98% in 2020 to 1.23% in 2023, but rebounded to 1.80% in 2024.
Deferred revenues: This liability increased significantly from 0.72% in 2020 to 1.69% in 2021, then steadily declined to 0.71% in 2024, suggesting reduction in deferred income over time.
Other current liabilities: There was a pronounced spike in 2021 at 13.74%, up from 7.47% in 2020, followed by a gradual decrease to 9.24% in 2024, yet remaining well above 2020 levels.
Current liabilities: The share of current liabilities relative to total liabilities and equity increased sharply from 16.81% in 2020 to 23.51% in 2021, then declined moderately to 20.15% by 2024.
Long-term debt, excluding current portion: This component decreased from 24.08% in 2020 to 16.68% in 2022, followed by a substantial increase to 27.17% in 2023, slightly easing to 26.90% in 2024.
Pension and postretirement benefit obligations: A consistent downward trajectory is observed, falling from 3.51% in 2020 to 0.96% in 2023, with a marginal increase to 0.99% in 2024.
Noncurrent deferred tax liabilities: This figure showed volatility, sharply declining from 2.63% in 2020 to 0.19% in 2021, with minor fluctuations thereafter and a rise to 0.99% in 2024.
Other taxes payable: A steady decrease occurred from 7.50% in 2020 to 2.86% in 2024, indicating reduced tax-related liabilities over the period.
Other noncurrent liabilities: This liability increased from 4.32% in 2020 to 7.30% in 2023, then slightly declined to 6.63% in 2024.
Noncurrent liabilities: The overall share decreased from 42.04% in 2020 to 29.99% in 2022, followed by a sharp increase to 39.48% in 2023 and a slight decrease to 38.38% in 2024.
Total liabilities: The total liabilities ratio fluctuated, decreasing from 58.84% in 2020 to 51.36% in 2022, then rising again to 60.58% in 2023 and settling at 58.53% in 2024.
Common stock, $0.05 par value: This component showed a slight but steady decline from 0.30% in 2020 to 0.21% in 2023, with a minor increase to 0.22% in 2024.
Additional paid-in capital: A downward trend is evident, dropping from 57.50% in 2020 to 40.90% in 2023, followed by a partial recovery to 43.86% in 2024.
Treasury stock, shares at cost: The negative percentage decreased in magnitude from -71.96% in 2020 to -50.55% in 2023, then increased again negatively to -53.78% in 2024, reflecting repurchase activity fluctuations.
Retained earnings: This item showed variability, declining from 62.74% in 2020 to 56.97% in 2021, rising to 63.72% in 2022, then falling sharply to 52.25% in 2023 and partially recovering to 54.70% in 2024.
Accumulated other comprehensive loss: The loss narrowed considerably from -7.58% in 2020 to -3.25% in 2021, then fluctuated moderately around -3.5% through 2024.
Total shareholders’ equity: Total equity fluctuated, increasing from 41.00% in 2020 to 48.51% in 2022, before declining to 39.30% in 2023 and rising again to 41.33% in 2024.
Equity attributable to noncontrolling interests: This minor component remained fairly stable, showing a slight decline from 0.15% in 2020 to 0.12% in 2023, with a slight uptick to 0.14% in 2024.
Total equity: Total equity displayed a parallel trend to total Pfizer shareholders' equity, rising from 41.16% in 2020 to a peak of 48.64% in 2022, declining to 39.42% in 2023, and recovering to 41.47% in 2024.
Total liabilities and equity: The sum of liabilities and equity consistently equals 100% across all years, confirming the data's completeness and balance.

Download chart